Coya Therapeutics, Inc.

Coya Therapeutics announced this morning unaudited third quarter 2024 financial results, as well as a corporate update. Read more in the latest press release here: https://lnkd.in/gduiJeAr $COYA #CoyaTherapeutics 

Coya Therapeutics announces that, as previously disclosed, Arun Swaminathan, Ph.D., has been promoted to Chief Executive Officer, effective today, November 1. He brings a wealth of strategic, business development, operational, and deal-making experience to help guide Coya in its next phase of corporate growth. Arun said: "We believe our combination therapeutic approach targeting neuroinflammation can unlock a new paradigm in neurodegenerative treatment. We are encouraged by data from the Phase 2 investigator-initiated trial in patients with mild to moderate Alzheimer’s disease treated with low-dose interleukin-2 (LD IL-2), shared at CTAD, validating our Treg platform." Read more in our latest press release: https://lnkd.in/egtQah8t $COYA #CoyaTherapeutics #CEO

#ICYMI, Coya Therapeutics announced positive results yesterday of an investigator initiated double-blind study of low-dose IL-2 in Alzheimer’s Disease, co-sponsored with Houston Methodist, Alzheimer's Association®, Bill & Melinda Gates Foundation, and National Institute on Aging (NIA) with support provided by Coya. The study strongly supports Coya’s approach to address #neurodegenerative diseases and once-a-month dosing, underscoring the importance of appropriate IL-2 dosing for maintaining Treg functionality and its associated effects on CSF biomarkers and cognitive outcomes. "Alireza Faridar, M.D., lead investigator and neurologist at Houston Methodist, saw the sustained expansion of Tregs throughout the period in which patients received IL-2. On the Treg endpoints, IL-2 performed best when given every four weeks, rather than every two weeks. The less frequent dosing regimen also looked better on the exploratory efficacy endpoints." Read more in this important article from Fierce Biotech: https://lnkd.in/eh-SJH7M $COYA #CoyaTherapeutics #Research #EndALZ

Progress around novel therapies informed by the biology of aging continues at CTAD Clinical Trials on Alzheimer's Disease. ADDF-funded Coya Therapeutics, Inc. reported positive results from their phase 2 trial of a novel drug that aims to enhance the function of regulatory T cells, which suppress #immune responses, showing the drug was safe and well-tolerated in #Alzheimers patients. This is one of many drugs in development that has the potential to be used in tandem with #antiamyloid therapies, moving us closer to treating Alzheimer's with a combination therapy approach. #CTAD24 https://bit.ly/3NKNIde via Reuters

Some quick stats from the important IL-2 Alzheimer’s study released today: 1. It met primary and secondary endpoints for safety and Treg cell population enhancement demonstrating target engagement. 2. Exploratory endpoints demonstrated stabilization of cognitive function in the every four-week dosing (LD IL-2 q4wks) treatment vs. placebo, which illustrated cognitive decline. 3. The findings support advancing LD IL-2 q4wks and LD IL-2 q4wks combination approaches in future studies. Find out more in the COYA presentation here: https://lnkd.in/eEwfk-VY $Coya #CoyaTherapeutics #EndALZ #Research

MAJOR NEWS: Coya Therapeutics announces positive results of a double-blind study of low-dose IL-2 in Alzheimer’s Disease at CTAD in Madrid, co-sponsored with Houston Methodist, Alzheimer's Association®, Bill & Melinda Gates Foundation, and the National Institute on Aging (NIA). Read the full press release here: https://lnkd.in/eZVEVUVg $COYA #CoyaTherapeutics #EndALZ #Research

Coya Therapeutics is excited to announce that we have been selected as a finalist for the Fierce Life Sciences Events Innovation Awards in the category Biotech Innovation! This recognition highlights the incredible work our team has done with COYA 302. Check out the full list of finalists here and mark your calendars for when the winners will be announced in December: https://lnkd.in/epdDMtPC #FierceLifeSciencesAwards #FierceInnovationAwards #CoyaTherapeutics

Coya Therapeutics is excited to share that CEO Howard Berman, PhD has been recognized on the PharmaVoice 100 list as an inspiring leader in the life-sciences space! Congratulations Howard, we are fortunate to have such a talented founder. Check out the full list here: https://lnkd.in/eB9K8vFe $COYA #CoyaTherapeutics #PV100 #LifeSciences #Pharma #PharmaVoice100 #PharmaLeaders

According to the Barrow Neurological Institute, some of the more common symptoms of neurodegenerative disorders may include: agitation, difficulty with movement, forgetfulness, memory loss, mood changes, and more. Be sure to got to regular checkups and talk to your doctor about any symptoms you may be experiencing. https://lnkd.in/ecFXSvgf #Alzheimers #Parkinsons #Neurodegenerative #FTD #ALS

According to The ALS Association, about 90% of ALS cases occur without any known family history or genetic cause with the remaining 10% of ALS cases are inherited through a mutated gene with a known connection to the disease. Most people who develop ALS are between the ages of 40 and 70, with an average age of 55 at the time of diagnosis and men are 20% more likely to develop the disease than women. Learn more about the causes of ALS and raise awareness to #EndALS here: https://lnkd.in/ew7rMt6 #EndALS #ALSresearch #CoyaTherapeutics